Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Beta-adrenoceptor polymorphisms.

K Leineweber1, R Büscher, H Bruck

  • 1Depts. of Pathophysiology and Nephrology, University of Essen School of Medicine, IG I., 9.OG, Hufelandstrasse 55, 45147, Essen, Germany. kirsten.leineweber@uni-essen.de

Naunyn-Schmiedeberg'S Archives of Pharmacology
|December 3, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A prospective cohort study to identify and evaluate endotypes of venous thromboembolism: Rationale and design of the Genotyping and Molecular Phenotyping in Venous ThromboEmbolism project (GMP-VTE).

Thrombosis research·2019
Same author

Cholestasis After Pediatric Liver Transplantation-Recurrence of a Progressive Familial Intrahepatic Cholestasis Phenotype as a Rare Differential Diagnosis: A Case Report.

Transplantation proceedings·2017
Same author

Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.

Clinical and experimental immunology·2016
Same author

[Retroperitoneal fibrosis: development of a biomarker profile for diagnosis and therapy monitoring].

Der Urologe. Ausg. A·2014
Same author

[Childhood ureteropelvic junction obstruction in a regional treatment center: spectrum and therapy].

Der Urologe. Ausg. A·2013
Same author

[Renal denervation: current state and future perspectives].

Herz·2012
Same journal

Modulation of the ACLY-AMPK axis by bempedoic acid suppresses NF-κB-driven inflammation, VEGF-Notch angiogenic crosstalk, and cell-cycle progression in Solid Ehrlich Carcinoma.

Naunyn-Schmiedeberg's archives of pharmacology·2026
Same journal

Alamandine attenuates stress-induced inflammation, oxidative stress, and intestinal histopathological alterations in a chronic unpredictable mild stress model of depression.

Naunyn-Schmiedeberg's archives of pharmacology·2026
Same journal

Rudolf Buchheim Award 2026: solanidine as a dietary derived CYP2D6 biomarker.

Naunyn-Schmiedeberg's archives of pharmacology·2026
Same journal

Integrative multi-omics analysis identifies SELL and PRF1 as key immune biomarkers and therapeutic targets in tuberculosis.

Naunyn-Schmiedeberg's archives of pharmacology·2026
Same journal

Topical ronomilast alone or combined with clobetasol ameliorates imiquimod-induced psoriasis in mice.

Naunyn-Schmiedeberg's archives of pharmacology·2026
Same journal

Role of CXCL16/ADAM10 signaling in methotrexate-induced nephrotoxicity and its modulation by simvastatin.

Naunyn-Schmiedeberg's archives of pharmacology·2026
See all related articles

Genetic variations in beta-adrenoceptor genes (beta(1)-, beta(2)-, beta(3)-) are common. These polymorphisms may not cause disease but can influence cardiovascular and metabolic functions, acting as risk factors or disease modifiers.

Area of Science:

  • Pharmacogenetics
  • Cardiovascular Physiology
  • Molecular Biology

Background:

  • Beta-adrenoceptor genes (beta(1), beta(2), beta(3)) exhibit known genetic polymorphisms.
  • Specific single nucleotide polymorphisms (SNPs) have been identified for each subtype, such as Ser49Gly and Gly389Arg for beta(1).

Purpose of the Study:

  • To review the functional consequences of beta-adrenoceptor gene polymorphisms.
  • To explore the potential phenotypic impacts on cardiovascular and metabolic functions.
  • To assess the role of these polymorphisms in disease pathophysiology.

Main Methods:

  • In vitro studies assessing receptor function.
  • Ex vivo analyses of tissue responses.
  • In vivo investigations in animal models and human studies.

Related Experiment Videos

Main Results:

  • Beta-adrenoceptor polymorphisms are unlikely to be direct disease-causing genes.
  • These genetic variations may act as risk factors for various conditions.
  • Polymorphisms can modify disease presentation and influence disease progression.

Conclusions:

  • Beta-adrenoceptor polymorphisms have functional consequences that warrant further investigation.
  • Their role as modifiers of disease risk and progression is significant.
  • Understanding these genetic variations is crucial for personalized medicine approaches in cardiovascular and metabolic disorders.